Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

 

Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators. 

§  A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.

§  Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).

§  An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  • Target Disease Indication 

§  Breast Cancer

§  Chronic Lymphocytic Leukemia

§  Colorectal Cancer

§  Head and Neck Cancer

§  Lung Cancer

§  Lupus Nephritis

§  Melanoma

§  Multiple Myeloma

§  Primary Sjögren's Syndrome

§  Others 

  • Target Immune Checkpoint

§  B7-H3

§  CD38

§  CD40

§  CD47

§  Others

  • Mechanism of Action

§  Inhibitory

§  Stimulatory

  • Therapeutic Modality

§  Monoclonal Antibody

§  Small Molecule

  • Type of Therapy 

§  Monotherapy 

§  Combination Therapy

  • Route of Administration

§  Intravenous

§  Subcutaneous

§  Others

  • Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific and the Rest of the World 

 

Key companies covered in the report - https://www.rootsanalysis.com/reports/303/request-sample.html

 

§  Bristol Myers Squibb

§  GlaxoSmithKline

§  Incyte

§  Novartis

§  Trillium Therapeutics

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Other Recent Offerings

1.      Neoantigen Targeted Therapies Market, 2019-2030

2.      Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

3.      Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more